Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7862798 | 0.79 | GABRA5 (0.45) | PNPRAB9ASMN1; SMN2NOS1GABRA5 | |
| SCHEMBL1107416 | 0.76 | SMN1; SMN2 (0.43) | RAB9ASMN1; SMN2NOS1GABRA5GABRB2 | |
| SCHEMBL1107382 | 0.76 | GABRA5 (0.44) | RAB9ASMN1; SMN2NOS1GABRA5GABRB2 | |
| SCHEMBL12742611 | 0.72 | GABRA5 (0.42) | RAB9ASMN1; SMN2NOS1GABRA5GABRB2 | |
| SCHEMBL9071396 | 0.72 | GABRA5 (0.42) | RAB9ASMN1; SMN2NOS1GABRA5GABRB2 | |
| SCHEMBL1107552 | 0.71 | RAB9A (0.46) | RAB9ASMN1; SMN2NOS1GABRA5GABRB2 | |
| SCHEMBL10624853 | 0.69 | GABRA5 (0.46) | RAB9ASMN1; SMN2NOS1GABRA5GABRB2 | |
| SCHEMBL12593680 | 0.68 | RAB9A (0.42) | RAB9ASMN1; SMN2NOS1GABRA5GABRB2 | |
| SCHEMBL5911714 | 0.68 | — | — | |
| SCHEMBL1107400 | 0.67 | RAB9A (0.45) | RAB9ASMN1; SMN2NOS1GABRA5GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1143955-A3 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| EP-1143955-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1112275-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | Metabasis Therapeutics, Inc. (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000038666-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000014095-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |